肝炎治療の世界市場分析:病気別(A型肝炎、B型肝炎、C型肝炎)、地域別(北アメリカ、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEA)、セグメント予測、2014-2025

【英語タイトル】Hepatitis Therapeutics Market Analysis By Disease Type (Hepatitis A, B, C) By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2014-2025

Grand View Researchが出版した調査資料(GVIEW707394)・商品コード:GVIEW707394
・発行会社(調査会社):Grand View Research
・発行日:2017年4月20日
・ページ数:80
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥559,350見積依頼/購入/質問フォーム
Multi UserUSD7,950 ⇒換算¥898,350見積依頼/購入/質問フォーム
Global/corporate LicenseUSD9,950 ⇒換算¥1,124,350見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、肝炎治療の世界市場について調査・分析し、肝炎治療の世界市場動向、肝炎治療の世界市場規模、市場予測、セグメント別肝炎治療市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global hepatitis therapeutics market is expected to reach USD 25.8 billion by 2025 according to a new report by Grand View Research, Inc. The key factors driving market growth include the rising number of infected population, growing consumption of alcohol & drugs, increase in global geriatric population, and improvement in access to hepatitis medicines.
Hepatitis is generally classified into two types based on the duration for which the patient suffers. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis.The population at a greater risk of hepatitis include people with HIV infection & HCV-infected sexual partners, who inject drugs & use intranasal drugs, recipients of infected blood products, and other population groups who live in unhygienic conditions.

According to the WHO, globally around 400 million people are infected with at least one form of hepatitis and every year nearly 1.4 people die due to the condition. Various government and private agencies are actively involved in the vaccination drive to prevent hepatitis. Hepatitis C leads to more serious complications compared to hepatitis A and B. As per WHO estimates, nearly 150 million are impacted by hepatitis C infection globally. Moreover, a significant number of hepatitis C patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.

Further Key Findings From the Report Suggest:

Due to very high prevalence of target disease coupled with subsequent increase in the treatment rate Hepatitis C accounted for the majority market share of 75.6% in 2016

In 2016, North America held the largest share of nearly 42.9%. The key factors attributed to the regions high share include high patient awareness levels and the presence of advanced healthcare infrastructure.

Asia Pacific is anticipated to witness the maximum growth with a CAGR of 5.8% over the forecast period. High economic development coupled with rapidly increasing healthcare expenditure are amongst key factors attributing to the regions high growth rate.

Key players include Gilead, Merck & Co. Inc., Johnson & Johnson, Bristol-Myers Squibb Company, and AbbVie Inc.

【レポートの目次】

Table of Contents

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
Chapter 3. Hepatitis Therapeutics Market Variables, Trends& Scope
3.1. Market Segmentation
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Key Opportunities Prioritized
3.4. Industry Analysis – Porter’s
3.5. Hepatitis Therapeutics Market-SWOT Analysis, By Factor (political & legal, economic and technological), 2015
Chapter 4. Hepatitis Therapeutics Market: Disease Type Estimates & Trend Analysis
4.1. Hepatitis Therapeutics Market Share by Disease Type, 2015 & 2025 (USD Million)
4.2. Hepatitis A
4.2.1. Market estimates and forecast, 2014 – 2025 (USD Million)
4.3. Hepatitis B
4.3.1. Market estimates and forecast, 2014 – 2025 (USD Million)
4.4. Hepatitis C
4.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
4.5. Others
4.5.1. Market estimates and forecast, 2014 – 2025 (USD Million)
Chapter 5. Hepatitis Therapeutics Market: Regional Outlook
5.1. Hepatitis Therapeutics Market share by region, 2015 & 2025 (USD Million)
5.2. North America
5.2.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.2.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.2.3. U.S.
5.2.3.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.2.3.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.2.4. Canada
5.2.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.2.4.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.3. Europe
5.3.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.3.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.3.3. Germany
5.3.3.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.3.3.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.3.4. UK
5.3.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.3.4.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.4. Asia Pacific
5.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.4.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.4.3. China
5.4.3.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.4.3.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.4.4. Japan
5.4.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.4.4.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.5. Latin America
5.5.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.5.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.5.3. Brazil
5.5.3.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.5.3.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.5.4. Mexico
5.5.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.5.4.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.6. Middle East & Africa
5.6.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.6.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
5.6.3. South Africa
5.6.3.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.6.3.2. Market estimates and forecast by disease type, 2014 – 2025 (USD Million)
Chapter 6. Competitive Landscape
6.1. Strategic Framework
6.2. Gilead Lifesciences
6.2.1. Company overview
6.2.2. Financial performance
6.2.3. Product benchmarking
6.2.4. Strategic initiatives
6.3. Bristol-Myers Squibb Co
6.3.1. Company overview
6.3.2. Financial performance
6.3.3. Product benchmarking
6.3.4. Strategic initiatives
6.4. Biocon
6.4.1. Company overview
6.4.2. Financial performance
6.4.3. Product benchmarking
6.4.4. Strategic initiatives
6.5. AbbVie
6.5.1. Company overview
6.5.2. Financial performance
6.5.3. Product benchmarking
6.5.4. Strategic initiatives
6.6. Merck & Co., Inc.,
6.6.1. Company overview
6.6.2. Financial performance
6.6.3. Product benchmarking
6.6.4. Strategic initiatives
6.7. Johnson & Johnson
6.7.1. Company overview
6.7.2. Financial performance
6.7.3. Product benchmarking
6.7.4. Strategic initiatives

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market summary
FIG. 5 Market trends & outlook
FIG. 6 Market segmentation & scope
FIG. 7 Market driver relevance analysis (Current & future impact)
FIG. 8 Market restraint relevance analysis (Current & future impact)
FIG. 9 Key Opportunity Priorities
FIG. 10 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 11 Porter’s Five Forces Analysis
FIG. 12 Hepatitis therapeutics market, Heat Map Analysis
FIG. 13 Hepatitis therapeutics market product outlook key takeaways
FIG. 14 Hepatitis therapeutics market: Disease type movement analysis
FIG. 15 Hepatitis A market, 2014 - 2025 (USD Million)
FIG. 16 Hepatitis B market, 2014 - 2025 (USD Million)
FIG. 17 Hepatitis C market, 2014 - 2025 (USD Million)
FIG. 18 Other hepatitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 19 Regional outlook, 2015 & 2024
FIG. 20 North America hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 21 U.S. hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 22 Canada hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 23 Europe hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 24 Germany hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 25 UK hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 26 Asia Pacific hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 27 China hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 28 Japan hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 29 Latin America hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 30 Brazil hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 31 Mexico hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 32 MEA hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 33 South Africa hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)

List of Tables

TABLE 1 hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 2 North America hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 3 U.S. hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 4 Canada hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 5 Europe hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 6 Germany hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 7 UK hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 8 Asia Pacific hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 9 China hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 10 Japan hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 11 Latin America hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 12 Brazil hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 13 Mexico hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 14 Middle East & Africa hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 15 South Africa hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)

★調査レポート[肝炎治療の世界市場分析:病気別(A型肝炎、B型肝炎、C型肝炎)、地域別(北アメリカ、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEA)、セグメント予測、2014-2025] (コード:GVIEW707394)販売に関する免責事項を必ずご確認ください。
★調査レポート[肝炎治療の世界市場分析:病気別(A型肝炎、B型肝炎、C型肝炎)、地域別(北アメリカ、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEA)、セグメント予測、2014-2025]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆